Neogen Corp (NEOG)
13.37
-0.30
(-2.19%)
USD |
NASDAQ |
May 21, 16:00
13.38
+0.01
(+0.07%)
After-Hours: 20:00
Neogen Enterprise Value: 3.615B for May 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 21, 2024 | 3.615B |
May 20, 2024 | 3.680B |
May 17, 2024 | 3.652B |
May 16, 2024 | 3.624B |
May 15, 2024 | 3.600B |
May 14, 2024 | 3.555B |
May 13, 2024 | 3.500B |
May 10, 2024 | 3.390B |
May 09, 2024 | 3.412B |
May 08, 2024 | 3.329B |
May 07, 2024 | 3.407B |
May 06, 2024 | 3.349B |
May 03, 2024 | 3.323B |
May 02, 2024 | 3.416B |
May 01, 2024 | 3.373B |
April 30, 2024 | 3.390B |
April 29, 2024 | 3.409B |
April 26, 2024 | 3.349B |
April 25, 2024 | 3.310B |
April 24, 2024 | 3.399B |
April 23, 2024 | 3.386B |
April 22, 2024 | 3.271B |
April 19, 2024 | 3.234B |
April 18, 2024 | 3.303B |
April 17, 2024 | 3.349B |
Date | Value |
---|---|
April 16, 2024 | 3.353B |
April 15, 2024 | 3.321B |
April 12, 2024 | 3.401B |
April 11, 2024 | 3.535B |
April 10, 2024 | 3.427B |
April 09, 2024 | 3.544B |
April 08, 2024 | 3.834B |
April 05, 2024 | 3.828B |
April 04, 2024 | 3.769B |
April 03, 2024 | 3.808B |
April 02, 2024 | 3.858B |
April 01, 2024 | 3.986B |
March 28, 2024 | 4.137B |
March 27, 2024 | 4.068B |
March 26, 2024 | 3.968B |
March 25, 2024 | 4.009B |
March 22, 2024 | 4.014B |
March 21, 2024 | 4.066B |
March 20, 2024 | 4.098B |
March 19, 2024 | 3.992B |
March 18, 2024 | 3.983B |
March 15, 2024 | 4.007B |
March 14, 2024 | 4.022B |
March 13, 2024 | 4.100B |
March 12, 2024 | 4.168B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.826B
Minimum
Aug 24 2022
5.797B
Maximum
Aug 15 2023
3.762B
Average
3.792B
Median
Dec 08 2020
Enterprise Value Benchmarks
Moderna Inc | 46.54B |
Regeneron Pharmaceuticals Inc | 100.98B |
Syros Pharmaceuticals Inc | 84.09M |
Disc Medicine Inc | 430.19M |
Amylyx Pharmaceuticals Inc | -250.88M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -2.022M |
Revenue (Quarterly) | 228.81M |
Total Expenses (Quarterly) | 216.79M |
EPS Diluted (Quarterly) | -0.01 |
Gross Profit Margin (Quarterly) | 51.08% |
Profit Margin (Quarterly) | -0.88% |
Earnings Yield | 0.04% |
Operating Earnings Yield | 2.38% |
Normalized Earnings Yield | 0.1572 |